Entering text into the input field will update the search result below

Vaxart: An Update

Oct. 02, 2021 10:55 AM ETVaxart, Inc. (VXRT)MRK28 Comments
C. C. Abbott profile picture
C. C. Abbott


  • On Oct. 1, Merck announced their oral COVID pill reduces hospitalization or death by 50% and the company will seek EUA as soon as possible.
  • Merck's good news seemed to cause a double-digit % stock price drop in COVID vaccine developers, including VXRT.
  • VXRT's COVID program is still on, but with an incredibly slow speed and an apparent lack of focus.
a snail crossing a road

Stefan Rotter/iStock via Getty Images


On Friday Oct. 1, Merck announced positive p3 interim data of their antiviral COVID treatment.

Molnupiravir, an oral antiviral pill, is said to reduce by "approximately 50%" the risk of hospitalization or death, compared to the placebo, in patients with mild or moderate COVID-19.

This article was written by

C. C. Abbott profile picture
Both my spouse and I have a DPhil from Oxford University. Mine is in Cell Physiology and his is in Bio-organic Chemistry. Our investment focus is on small/micro cap biotech. My SA articles are not stock tips/predictions, financial advice or substitutes for your own due diligence. I'm not a financial adviser. I wrote SA articles for myself and for anyone who find reading & considering SA articles helpful in their investment research. Wishing you the best in seeking & finding alpha through biotech investing!

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I am long-only biotech investor. I am long in AVRO, AVXL, EDSA, FRLN, KRYS, LOGC, LRMR, SIOX I am not a financial advisor and my SA articles are not financial recommendation. Conduct your own research before any decision or action, as each person is responsible for their own decision/action.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.